Related Experiment Videos
WNT5A expression in human breast cancer.
A C A Leris1, T R Roberts, W G Jiang
1St George's Hospital, Blackshaw Road, Tooting, London SW17 OQT, UK.
Anticancer Research
|May 5, 2005
Summary
Wnt5a mRNA levels are lower in breast tumors, especially in advanced stages and ER-negative disease, suggesting Wnt5a acts as a tumor suppressor gene. This finding has potential clinical applications in breast cancer treatment.
Area of Science:
- Molecular biology
- Oncology
- Genetics
Background:
- Wnt family proteins are crucial for cell adhesion and growth.
- Wnt5a's role in cancer is complex, acting as both an oncogene and tumor suppressor.
- Wnt5a signaling can activate distinct pathways (Wnt/beta-catenin or Wnt/Ca++), influencing its function.
Purpose of the Study:
- To investigate Wnt5a mRNA expression in human breast cancer.
- To correlate Wnt5a expression levels with clinical parameters and patient outcomes.
Main Methods:
- Real-time quantitative PCR was used to measure Wnt5a mRNA levels.
- Analysis included 120 malignant breast tumors and 33 normal breast tissues.
- Expression levels were correlated with tumor stage, nodal involvement, grade, metastasis, and survival.
Main Results:
- Wnt5a mRNA levels were significantly lower in tumor tissues compared to normal tissues.
- Lower Wnt5a expression correlated with higher tumor stage (Nottingham Prognostic Index).
- In ER-negative breast cancer patients, reduced Wnt5a levels were linked to worse clinical outcomes.
Conclusions:
- Wnt5a mRNA levels decrease in breast cancer, with further reduction in more aggressive disease.
- These findings support the hypothesis that Wnt5a functions as a tumor suppressor gene.
- Wnt5a may have potential as a biomarker or therapeutic target in breast cancer.